Archive · 12 Aug 2025
Eli Lilly's New Weight Loss Pill Shows Promising Results
Imagine a new pill from Eli Lilly that helps people lose weight!
It's called orforglipron and it works without needing to change what you eat.
In a study, people lost a good amount of weight.
The pill also seems to help with heart health and diabetes.
But, like some other medicines, it can cause some tummy troubles for a few people.
Eli Lilly hopes to get the pill approved by the government so it can be available in a few years.
It may be easier to get than other weight loss shots.
Eli Lilly's oral GLP-1 pill, orforglipron, showed significant weight loss in a Phase 3 trial without requiring dietary restrictions.
Participants lost an average of 12.3 kilograms over 72 weeks.
The pill also lowered markers of heart risk and improved blood sugar levels in those with Type 2 diabetes.
Common side effects included nausea, vomiting, diarrhea, and constipation.
Eli Lilly aims to submit orforglipron for FDA approval this year, potentially available in 2026.
- Who
- Eli Lilly developed the pill, and it was tested on adults with obesity.
- What
- A new oral GLP-1 pill called orforglipron that aids in weight loss.
- When
- The Phase 3 trial lasted 72 weeks, and potential availability is expected in 2026.
- Where
- Trials were conducted, and it will be available to consumers.
- Why
- The pill aims to offer an alternative weight loss solution, potentially easier to use and more accessible than existing injectable treatments.
Potential Benefits
Potential Risks
Efficacy vs. Side Effects
Potential Benefits
Weight Loss: The pill promotes significant weight loss.
Potential Risks
Side Effects: The pill can cause side effects such as nausea, vomiting, and diarrhea.
- Drug Name
- Orforglipron
- Developer
- Eli Lilly
- Trial Type
- Phase 3
- Average Weight Loss
- 12.3 kilograms
- Trial Duration
- 72 weeks
- Potential FDA Approval
- Later this year
- Possible Launch Year
- 2026